ADAM17 and cancer: However, the clinical efficacy of SMIs has been hampered by their instability and indiscriminate targeting of other proteases (e.g., ADAM10) leading to high toxicity, thus paving the way for other ADAM17‐based treatment modalities (e.g., antibody) to be explored in cancer models (Fridman et al, 2007; Richards et al, 2012; Rios‐Doria et al, 2015; Ye et al, 2017).